Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 37
- Registration Number
- NCT02137837
- Locations
- 🇺🇸
St. Patrick Hospital, Missoula, Montana, United States
🇺🇸Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States
🇺🇸Clackamas Radiation Oncology Center, Clackamas, Oregon, United States
Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 79
- Registration Number
- NCT02137538
- Locations
- 🇺🇸
Lucile Packard Children's Hospital, Palo Alto, California, United States
Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 600
- Registration Number
- NCT02097459
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
- First Posted Date
- 2014-03-24
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 90
- Registration Number
- NCT02095184
- Locations
- 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 79
- Registration Number
- NCT02093351
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2014-02-26
- Target Recruit Count
- 180
- Registration Number
- NCT02072512
- Locations
- 🇨🇳
307 Hospital, Beijing, Beijing, China
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 198
- Registration Number
- NCT02057133
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Highlands Oncology Group - Duplicate 2, Rogers, Arkansas, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Impact of Endogenous E2 on SSI and GH Rebound
- Conditions
- Interventions
- First Posted Date
- 2014-01-03
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 62
- Registration Number
- NCT02026973
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 160
- Registration Number
- NCT01989780
- Locations
- 🇯🇵
Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan
Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT01972984
- Locations
- 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.